The longer the better? Four years of durable, initially boosted protease treatment.
Katzenstein
David
D
Division of Infectious Disease, Stanford University, Stanford, California 94305-5107, USA.
D023241:Antiretroviral Therapy, Highly Active; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000009:adverse effects / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D017211:Treatment Failure
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D018119:Stavudine; D019438:Ritonavir